Cyclin-Dependent Kinase 9
"Cyclin-Dependent Kinase 9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A multifunctional CDC2 kinase-related kinase that plays roles in transcriptional elongation, CELL DIFFERENTIATION, and APOPTOSIS. It is found associated with CYCLIN T and is a component of POSITIVE TRANSCRIPTIONAL ELONGATION FACTOR B.
| Descriptor ID |
D042863
|
| MeSH Number(s) |
D08.811.641.752 D08.811.913.696.620.682.700.646.500.500.750 D12.644.360.250.067.900 D12.776.167.200.067.900 D12.776.476.250.067.900 D12.776.930.955.500.500
|
| Concept/Terms |
Cyclin-Dependent Kinase 9- Cyclin-Dependent Kinase 9
- Cyclin Dependent Kinase 9
- PITALRE Kinase
- Cdk9 Protein Kinase
- CDK9 Kinase
- Cdc2-related Kinase PITALRE
- Cdc2 related Kinase PITALRE
- Kinase PITALRE, Cdc2-related
- PITALRE, Cdc2-related Kinase
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase 9".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase 9".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase 9" by people in this website by year, and whether "Cyclin-Dependent Kinase 9" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 2 | 2 |
| 2004 | 2 | 0 | 2 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 3 | 0 | 3 |
| 2012 | 3 | 2 | 5 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 2 | 3 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase 9" by people in Profiles.
-
Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer. 2022 10; 3(10):1211-1227.
-
Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J. 2022 01 31; 12(1):23.
-
Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. Cell Chem Biol. 2021 02 18; 28(2):134-147.e14.
-
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. Leukemia. 2020 06; 34(6):1646-1657.
-
TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb. Elife. 2019 01 17; 8.
-
Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway. Am J Manag Care. 2018 08; 24(16 Suppl):S356-S365.
-
Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. Br J Cancer. 2018 02 06; 118(3):388-397.
-
BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. Mol Cell. 2017 Jul 06; 67(1):5-18.e19.
-
Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017 Apr 25; 8(17):28696-28710.
-
The HIV-1 Tat Protein: Mechanism of Action and Target for HIV-1 Cure Strategies. Curr Pharm Des. 2017; 23(28):4098-4102.